Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for approval in asthma.

Advertisement

Related Content

Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
FDA Calls For Class-Wide REMS For LABA Asthma Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel